Mostrar el registro sencillo del ítem

dc.contributor.authorCascallar, M.
dc.contributor.authorAlijas Pérez, Sandra
dc.contributor.authorPensado-López, A.
dc.contributor.authorVázquez Ríos, Abi Judith
dc.contributor.authorSánchez, L.
dc.contributor.authorPIÑEIRO CID, ROBERTO 
dc.contributor.authorDe La Fuente Freire, María 
dc.date.accessioned2025-08-25T12:40:20Z
dc.date.available2025-08-25T12:40:20Z
dc.date.issued2022
dc.identifier.citationCascallar M, Alijas S, Pensado-López A, Vázquez-Ríos AJ, Sánchez L, Piñeiro R, et al. What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine. Cancers. MDPI; 2022;14(9).
dc.identifier.issn2072-6694
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/628009b13333e458234bb857*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20496
dc.description.abstractCancer causes millions of deaths each year and thus urgently requires the development of new therapeutic strategies. Nanotechnology-based anticancer therapies are a promising approach, with several formulations already approved and in clinical use. The evaluation of these therapies requires efficient in vivo models to study their behavior and interaction with cancer cells, and to optimize their properties to ensure maximum efficacy and safety. In this way, zebrafish is an important candidate due to its high homology with the human genoma, its large offspring, and the ease in developing specific cancer models. The role of zebrafish as a model for anticancer therapy studies has been highly evidenced, allowing researchers not only to perform drug screenings but also to evaluate novel therapies such as immunotherapies and nanotherapies. Beyond that, zebrafish can be used as an "avatar" model for performing patient-derived xenografts for personalized medicine. These characteristics place zebrafish in an attractive position as a role model for evaluating novel therapies for cancer treatment, such as nanomedicine.en
dc.description.sponsorshipThis research was funded by the Instituto de Salud Carlos IIIISCIII and the European Regional Development Fund (FEDER) (AC18/00107, AC18/00045, PI21/01262); by the ERA-NET EURONANOMED III project METASTARG (grant number JTC2018-045) and the ERA-NET EURONANOMED III project PANIPAC (grant number JTC2018/041); and by Axencia Galega de Innovacion (GAIN), Conselleria de Economia, Emprego e Industria (IN607B2021/14). R.P. was funded by RocheChus Joint Unit (IN853B 2018/03) funded by Axencia Galega de Innovacion (GAIN), Conselleria de Economia, Emprego e Industria. A.P-L. is supported by the Xunta de Galicia Pre-doctoral Fellowship (ED481A-2018/095). L.S. acknowledges the funding given by Conselleria de Educacion, Universidade e Formacion Profesional, Xunta de Galicia local government (ref. ED431C 2018/28).en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleWhat Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine*
dc.typeReviewen
dc.authorsophosCascallar, M. M.
dc.authorsophosAlijas, S.
dc.authorsophosPensado-López, A.
dc.authorsophosVázquez-Ríos, A. J.
dc.authorsophosSánchez, L.
dc.authorsophosPiñeiro, R.
dc.authorsophosde la, Fuente
dc.identifier.doi10.3390/cancers14092238
dc.identifier.sophos628009b13333e458234bb857
dc.issue.number9
dc.journal.titleCancers*
dc.page.initialnull
dc.relation.projectIDEuropean Regional Development Fund (FEDER) [AC18/00107, AC18/00045, PI21/01262]; ERA-NET EURONANOMED III project METASTARG [JTC2018-045]; ERA-NET EURONANOMED III project PANIPAC [JTC2018/041]; Axencia Galega de Innovacion (GAIN), Conselleria de Economia, Emprego e Industria [IN607B2021/14]; RocheChus Joint Unit - Axencia Galega de Innovacion (GAIN), Conselleria de Economia, Emprego e Industria [IN853B 2018/03]; Xunta de Galicia Pre-doctoral Fellowship [ED481A-2018/095]; Conselleria de Educacion, Universidade e Formacion Profesional, Xunta de Galicia local government [ED431C 2018/28]; Instituto de Salud Carlos IIII-SCIII
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/14/9/2238/pdf?version=1654485446;https://mdpi-res.com/d_attachment/cancers/cancers-14-02238/article_deploy/cancers-14-02238-v2.pdf?version=1654485446es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordIDISes
dc.subject.keywordCHUSes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo de Revisiónes
dc.volume.number14


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional